Avexa Report issue

For profit Phase 3
Founded: Melbourne Australia (2004)
Status: Defunct (2012)

Organization Overview

First Clinical Trial
2005
NCT00126880
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Avexa Ltd

Active Ingredients

Drugs in Phase 3 Trials (2)

apricitabine (6 trials)

lamivudine (epivir) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Communicable Diseases (Phase 3)

HIV Infections (Phase 3)

Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 2